This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

This study has been completed.
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
University of Hawaii
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT01386970
First received: June 28, 2011
Last updated: May 1, 2017
Last verified: May 2017
June 28, 2011
May 1, 2017
May 2005
July 2008   (Final data collection date for primary outcome measure)
To compare zidovudine (ZDV)- and lamivudine (3TC)-triphosphate concentrations in women versus men. [ Time Frame: 12 days ]
1st dose and day 12 dose compared after 12 days
To compare zidovudine (ZDV)- and lamivudine (3TC)-triphosphate concentrations in women versus men. [ Time Frame: 12 days ]
1st dose and day 12 dose compatred after 12 days
Complete list of historical versions of study NCT01386970 on ClinicalTrials.gov Archive Site
  • Change in mitochondrial DNA before and after blood analysis [ Time Frame: day 12 (HIV negative) up to 2 years (HIV-infected) ]
    To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA
  • To investigate relationships between ZDV- and 3TC-triphosphate concentrations and the incidence of clinical side effects. [ Time Frame: day 12 (HIV-negative) various longer duration in times (HIV-infected) ]
    To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA
  • Drug levels compared between HIV negative and HIV infected subject [ Time Frame: 1st dose and day 12 dose ]
    To compare ZDV- and 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.
  • Change in mitochondrial DNA before and after blood analysis [ Time Frame: day 12 (HIV negative) up to 2 years (HIV-infected) ]
    To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA
  • To investigate relationships between ZDV- and 3TC-triphosphate concentrations and the incidence of clinical side effects. [ Time Frame: day 12 (HIV-negative) various longer duration in times (HIV-infected) ]
  • Drug levels compared between HIV negative and HIV infected subject [ Time Frame: 1st dose and day 12 dose ]
    To compare ZDV- and 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.
genetic associations with ZDV and 3TC disposition [ Time Frame: study time frame ]
Variability in genes encoding proteins influencing the disposition of ZDV and 3TC will be correlated with ZDV and 3TC disposition.
Not Provided
 
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Sex and Disease Dependent Nucleoside Analog Toxicity
This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection. Additionally, markers of side effects were correlated with blood levels of the drugs. The hypothesis was that women and those with HIV would have higher drug levels, as well as markers of side effects.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Other
HIV
Drug: zidovudine 300mg and lamivudine 150mg as Combivir
twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
  • Active Comparator: HIV-negative
    This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
    Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir
  • Active Comparator: HIV-infected
    This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
    Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
51
July 2010
July 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+); HIV-negative volunteers must have a negative HIV-ELISA.
  • Age 18 to 55 years;
  • Either antiretroviral naïve, or no HIV-therapy in the preceding 6 months;
  • Planned antiretroviral regimen includes standard doses of ZDV plus 3TC as part of the antiretroviral regimen. Once- or twice-daily 3TC will be allowed.

Exclusion Criteria:

  • Any medical condition that in the opinion of the investigators would jeopardize the intent of the study.
  • In the opinion of the investigator, any concomitant immunomodulatory medications, chemotherapeutic agents, investigational drugs, and alternative therapies, including, glucocorticoids, recombinant growth factors or cytokines (e.g. Granulocyte-macrophage colony-stimulating factor, Granulocyte colony-stimulating factor, interferon-alpha or gamma, human growth hormone, etc), ribavirin, birth-control pills, and sex hormones that could interfere with the cellular pharmacology of the study medications;
  • Concomitant medications that interfere with renal drug clearances including, tenofovir, adefovir, cidofovir, ganciclovir, probenecid, or any similarly problematic medication in the opinion of the investigators;
  • Concomitant warfarin or daily aspirin (to prevent excess bleeding from biopsy).
  • Pregnancy or a plan to become pregnant, or menopause;
  • Any > or = grade II abnormality in hemoglobin, absolute neutrophil count, routine liver function tests, serum creatinine, or other organ function abnormalities.
  • Any medical or personal condition that, in the judgment of the investigators, may influence the subject's ability to comply with study conditions, such as active mental illnesses, or plans to leave the geographical area.
  • Inability to give informed consent.
  • Triple nucleoside analog reverse transcriptase regimens.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01386970
04-1101
R01AI064029 ( US NIH Grant/Contract Award Number )
Yes
Not Provided
No
No plan to share.
University of Colorado, Denver
University of Colorado, Denver
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Hawaii
Principal Investigator: Peter L. Anderson, PharmD University of Colorado Denver and Health Sciences Center
University of Colorado, Denver
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP